VSV-hIFNbeta-NIS
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for VSV-hIFNbeta-NIS, covering 2024-10-29 to 2024-10-29. Get the full timeline:
Most recent: Clinical Trial Update: VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer [Phase 1]